

1 **Early recovery of leukocyte subsets is associated with progression-free survival in patients with**  
2 **inoperable stage III NSCLC after multimodal treatment: a prospective explorative study**

3

4 Thomas P. Hofer<sup>1</sup>, Alexander E. Nieto<sup>2</sup>, Lukas Käsmann<sup>2,3,4</sup>, Carolyn J. Pelikan<sup>1</sup>, Julian Taugner<sup>2</sup>, Saloni  
5 Mathur<sup>1</sup>, Chukwuka Eze<sup>2</sup>, Claus Belka<sup>2,3,4</sup>, Farkhad Manapov<sup>2,3,4,\*</sup>, Elfriede Nößner<sup>1,\*</sup>

6

7 <sup>1</sup>Helmholtz Zentrum München, Immunoanalytics – Tissue Control of Immunocytes, Munich,  
8 Germany; <sup>2</sup>Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany;

9 <sup>3</sup>German Center for Lung Research (DZL), partner site Munich, Germany; <sup>4</sup>German Cancer

10 Consortium (DKTK), partner site Munich, Germany; \* these authors contributed equally to this work

11

12 **Corresponding author:** Thomas P. Hofer, [thomas.hofer@helmholtz-munich.de](mailto:thomas.hofer@helmholtz-munich.de), Helmholtz Center

13 Munich, Feodor-Lynen-Str. 21, D-81377 Munich

14

15 **Short title:** Radio-Immune-Lung-Study-NSCLC

16

17 **Highlights**

- 18 • Early increase within 3 weeks after thoracic radiation therapy (TRT) of CD8+ T cells is  
19 associated with favorable progression free survival (PFS).  
20 • Low standard deviation in IL-6 plasma concentration in consecutive measurements after TRT  
21 is associated with favorable PFS.  
22 • Absolute lymphocyte counts at treatment begin had no predictive value for treatment  
23 outcome.

24

25 **Funding statement:** none

26

27

28 **Key words**

29 Non-small cell lung cancer, linear discriminant analysis, peripheral blood markers, area under curve  
30 analysis, immune checkpoint therapy, progression-free survival, overall survival, CD4+ T cells, CD8+ T  
31 cells, NK cells, B cells, Neutrophils, Eosinophils

32

33 **Abbreviations**

34 AB Antibody  
35 ALC Absolute Lymphocyte Count  
36 ASP Antibody Staining Panel  
37 cCRT concurrent Chemoradiotherapy  
38 Durva Durvalumab  
39 FCM Flow Cytometry  
40 FCS Fetal Calf Serum  
41 FL Fluorochrome  
42 Gy Gray  
43 ICI Immune Checkpoint Inhibition  
44 IQR Inter Quantile Range  
45 LDA Linear Discriminant Analysis  
46 LQR Lower Quartile Range  
47 mo Month(s)  
48 Nivo Nivolumab  
49 NLR Neutrophil-Lymphocyte-Ratio  
50 NSCLC Non-small cell lung cancer  
51 OS Overall Survival  
52 PFS Progression-free Survival  
53 RT Radiation Therapy  
54 TRT Thoracic Radiotherapy  
55 UQR Upper Quantile Range  
56 y Year(s)

57

58 **Abstract**

59

60 Background

61 We explored the dynamic changes of major leukocyte subsets during definitive treatment of patients  
62 with inoperable stage III NSCLC lung cancer and correlated it to survival to identify subpopulations  
63 associated with maximal patient benefit.

64

65 Methods

66 We analyzed peripheral blood of 20 patients, either treated with thoracic radiotherapy (RT),  
67 concurrent chemo-radiotherapy (cCRT), or cCRT with additional immune-checkpoint inhibition  
68 therapy. Blood samples were collected at 9 timepoints before, during, and up to 1 year post  
69 treatment and analyzed by multi-color flow cytometry. Statistical analysis was conducted for  
70 leukocyte subpopulations, IL-6, progression-free survival (PFS) and overall survival (OS).

71

72 Results

73 Increase of absolute lymphocyte counts (ALC) after the end of RT until 6 months thereafter was a  
74 predictor of PFS. Baseline lymphocyte counts showed no significant correlation to PFS or OS. Early  
75 recovery of absolute counts (AC) at 3 weeks after RT, total CD3+ T-cells, and CD8+ cytotoxic T-cells  
76 distinguished those patients with favorable PFS ( $\geq 12$  months) from all other patients. Discriminant  
77 analysis identified B-cells, neutrophil-lymphocyte-ratio (NLR), CD4+ T-helper-cells, and NK-cells as  
78 predictors of favorable PFS. High variability in IL-6 plasma concentration of consecutive  
79 measurements within 6 months after the end of RT correlated negatively with PFS.

80

81 Conclusion

82 Our results suggest that two parameters commonly assessed in clinical routine, can be used to  
83 predict patient outcome. These are: early increase in CD8+ T-cell lymphocyte-count and variability in

84 IL-6 plasma concentration, that are correlated to patients with favorable, respectively, poor outcome  
85 after definitive therapy independent of treatment regimen.

86

87 **Key words**

88 Non-small cell lung cancer, linear discriminant analysis, peripheral blood markers, area under curve  
89 analysis, immune checkpoint therapy, progression-free survival, overall survival, CD4+ T cells, CD8+ T  
90 cells, NK cells, B cells, Neutrophils, Eosinophils

91

92 **Background**

93 Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, and prognosis  
94 remains poor with a low 5-year survival rate, only up to 36% of patients with an advanced stage  
95 experiencing sustained clinical benefit from therapy [1]. Treatment advances were achieved by  
96 introducing immune checkpoint therapy (ICI) as monotherapy or in addition to chemo-radiotherapy  
97 [2, 3].

98 There is a medical need to not only find more effective therapies but also to identify those patients  
99 who are likely to benefit from added ICI or should be spared the side effects if ICI is ineffective [4].

100 Ongoing efforts are being made to identify suitable biomarkers to predict benefit or non-response,  
101 preferably obtained from easily and repeatedly accessible biomaterial like venous peripheral blood.

102

103 In this prospective single-center study we aimed to explore whether the dynamics of defined  
104 lymphocyte subsets might be suitable to predict survival. We performed immune monitoring on  
105 patients who underwent therapy for inoperable stage III NSCLC. We prospectively report on  
106 characteristics of absolute T-cell counts (total CD3+ T-cells, CD3+CD4+, and CD3+CD8+ T-cells), B-  
107 cells, NK-cells, neutrophils, thrombocytes, and IL-6 plasma levels regarding patient treatment and  
108 outcome (progression free survival, PFS, and overall survival, OS).

109

## 110 **Material and Methods**

### 111 **Patients, Controls, Blood Sampling, Treatment**

112 Blood samples from patients with unresectable stage III non-small cell lung cancer (NSCLC; 8<sup>th</sup> TNM  
113 staging system) without distant metastases were obtained before as well as during treatment and  
114 follow-up at the Clinic for Radiation Oncology of the LMU University Hospital, Munich. All patients  
115 were included in this study on a voluntary basis and provided written informed consent. The study  
116 was approved by the Human Ethics Committee of the Ludwig-Maximilians-University of Munich  
117 reference no. 17-632 and conducted in accordance with the Declaration of Helsinki.

118 Twenty patients (17 male, 3 female), first diagnosed with a median age of 65.5 years (range 34 to 79)  
119 were enrolled in this study (Tab. 1; Fig. S1).

120

121 Tab. 1: Characteristics of patients with NSCLC and healthy controls

122

123	Patients	n=20
124	Age (mean SD) (years)	62.5 ± 13.75
125	(median / range) (years)	65.5 / 34-79
126	Sex (male / female)	17 / 3
127	Therapy (RT, cCRT, cCRT-ICI, salvage therapy)	2 / 12 / 7 / 3
128	Adenocarcinoma	11
129	Squamous cell carcinoma	8
130	Undiff. NSCLC	1
131	Distant metastasis	8
132	Local remission	9
133	Death	7
134	Smokers (none / active / ex)	1 / 7 / 12
135	Smoking history > 50 pack years	8
136		
137	Healthy Controls	n= 9
138	Age (mean SD) (years)	35 ± 13.74
139	(median / range) (years)	30 / 24-59
140	Sex (male / female)	1 / 8
141	Smokers (none / active / ex)	8 / 1 / 0

142

143

144 Blood samples were collected before onset of therapy (A.1 at week 0), twice during (A.2 and A.3 at  
145 week 2 and 5, respectively) and at the end of radiotherapy (RTend at week 7), and during follow up  
146 (C.1 to C.5 at week 10, 20, 35, 48, and 60) (Fig. S1).

147 The controls constituted of 9 apparently healthy individuals (CTRL) with a median age of 30y (range  
148 24 to 59) at the timepoints of blood sampling; 1 male and 8 females (Fig. 1, Tab. 1). Samples were  
149 processed and analyzed simultaneously and identically to the patient samples.

150

151 Patient treatment modality was concluded at the discretion of the treating physician based on clinical  
152 standards and following multidisciplinary tumor board discussion. Two patients received RT alone, 18  
153 patients were treated with platinum-based concurrent cCRT, and 7 patients received additional ICI  
154 either concurrently (nivolumab) or sequentially (durvalumab). More detail is provided in Fig. S1.

155

#### 156 **Leukocyte Phenotyping**

157 Blood was collected using 3K-EDTA S-Monovette tubes (Sarstedt, Germany) and samples were  
158 analyzed within 3 hours. Using 100  $\mu$ l of whole blood, erythrocytes were lysed, cells were surface-  
159 stained, spiked with counting beads and analyzed on a BD LSRII flow cytometer. Details on sample  
160 preparation, staining and gating strategy, cell type identification are given in the supplements (Fig.  
161 S2, Tab. S1).

162 Neutrophil and lymphocyte counts used to calculate Neutrophil-Lymphocyte-Ratio (NLR), eosinophil  
163 counts, and IL-6 plasma levels were obtained from clinical routine blood testing (clinical chemistry).

164

#### 165 **Analysis of immunocyte population dynamics and variation of IL-6 plasma concentration**

166 To describe the dynamic changes in absolute cell counts during the period after treatment end  
167 (RTend), we calculated the area under the curve (AUC) of consecutive blood sampling timepoints  
168 from RTend-C.3 (6 mo after treatment end). Low or high AUC reflect higher or lower AC in this  
169 period.

170 For analysis of variation of IL-6 concentration during RTend-C.3, standard deviation of absolute  
171 values at three consecutive timepoints after RTend were calculated and stratified according to  
172 groups with poor (<6 mo), intermediate ( $\geq 6 < 12$  mo), and favorable ( $\geq 12$  mo) PFS.

173

#### 174 **Statistical analysis**

175 This study was designed as a discovery study with the intention of generating hypotheses. Statistical  
176 tests were Student's t-test, Kruskal Wallis test, Log-rank (Mantel-Cox), Fisher's Exact test, and Log-  
177 Rank for trend. Differences were considered significant with  $p < 0.05$ . For multivariate discriminant  
178 analysis (MDA), and heatmap visualization, R statistical software V4.2.1 and the packages  
179 ComplexHeatmap V2.12.1, Dplyr V1.0.10, Plyr V1.8.7, missMDA V1.18, Openxlsx V4.2.5, Stats V4.3.0  
180 and Tidyverse 1.3.2 were used.

181 For MDA, we used the ggord package from Marcus W. Beck (2017). ggord: Ordination Plots with  
182 ggplot2. R package version 1.0.0 <https://zenodo.org/badge/latest/doi/35334615>. For generating  
183 graphs and Kaplan-Meier curves, GraphPad Prism V9, and for MANOVA analysis Past V4.11 [5] were  
184 used.


185

#### 186 **Results**

##### 187 **No prognostic value of ALC for PFS or OS at any single timepoint before, during and after treatment**

188 Baseline ALC were highly heterogenous in the NSCLC patient cohort (n=20) with a higher median of  
189 1.57 (range 4.65-0.58) Gcells/L of ALC compared to the controls (n=9, median 1.29, range 2.69-0.80  
190 Gcells/L). All patients experienced moderate to severe lymphocytopenia (assessed per the Common  
191 Terminology Criteria for Adverse Events v5.0) during RT/cCRT with median ALC of 0.75 (range 1.80-  
192 0.21), 0.61 (range 4.36-0.15), and 0.46 (range 2.57-0.21) Gcells/L at timepoint A.2, A.3, and RTend,  
193 respectively (grey area in Fig.1). ALC recovered after RTend reaching median values of 1.10 (range

194 3.85-0.09) Gcells/L at C.1 (3 wks after RTend), 1.09 (range 6.04-0.09) Gcells/L at C.2 (3 mo after  
 195 RTend), 1.21 (range 4.00-0.08) Gcells/L at C.3 (6 mo after RTend), 1.72 (range 2.99-0.77) Gcells/L at  
 196 C.4 (10 mo after RTend), and 1.19 (range 5.47-0.54) Gcells/L at C.5 (13 mo after RTend). The recovery  
 197 varied across patients, some with poor others with good increase in cell counts.



198

199 **Fig. 1** ALC in NSCLC patients' peripheral blood (n=20) before (A.1), during (A.2, A.3, RTend), and up to 1 y (C.1-C.5) after  
 200 treatment. Grey violin represents ALC of CTRL (n=9). Each dot represents an individual, color codes the PFS group of the  
 201 patients. Grey area represents the interval of radio- (RT) or chemoradiotherapy (cCRT), color-coded lines connect the  
 202 median of ALC of each PFS group at the different timepoints. The bold dashed line in the violins indicate median, light  
 203 dotted lines the lower and upper quartile. Student's t test, \* p<0.05, \*\* p<0.01, \*\*\*p<0.001 compared to A.1; ⊕ p<0.05  
 204 compared to preceding timepoint.

205

206 Patients were stratified according to PFS after RTend, with poor PFS<6 mo indicated by purple dots,  
 207 intermediate PFS≥6<12 mo shown as black dots, and favorable PFS≥12 mo depicted as green dots.

208 Patients with favorable PFS had on average an early increase in ALC within 3 weeks after RTend (C.1),  
 209 peaking at timepoint C.2 (14 weeks after RTend) and return to a median ALC comparable to the CTRL.

210 Patients with poor and intermediate PFS had a delayed increase in ALC with a peak in cell counts at  
 211 C.4 (40 weeks). Although these data indicated that an early recovery of ALC may be beneficial with




212 regards to PFS, there was high ALC heterogeneity within the PFS groups: 3 of 6 patients in the  
213 favorable PFS group had no early ALC peak at 14 weeks.

214

## 215 Dynamics of leukocyte subpopulations after RT

216 Favorable PFS group ( $\geq 12$  mo) showed significant increase in AC from RTend to C.1 for lymphocytes,  
217 total T-cells, and CD8+ T-cells. For the other PFS groups, lymphocytes and CD4+ T-cells did not  
218 increase, or the increase occurred later (between RTend and C.3) (Fig. 2, Fig. S4). This was observed  
219 for total lymphocytes as well as total CD3+ T-cells and CD8+ T-cells, but not for CD4+ T-cells (for  
220 medians and p-values see Tab S1). This implies that an early increase of lymphocytes, total CD3+ T-  
221 cells, or CD8+ T-cells within 3 or 14 weeks after RTend (C.1, or C.2) identifies patients with a  
222 favorable progression-free survival-time  $\geq 12$  mo.



223

224 **Fig. 2** Absolute cell counts of lymphocytes, CD3+ T-cells, CD4+ T-cells, and CD8+ T-cells (analyzed with flow cytometry) at  
225 timepoints RTend, C.1, C.2, and C.3 within the different PFS groups (PFS<6 mo (red), PFS  $\geq 6$ <12 mo (grey), PFS  $\geq 12$  mo  
226 (green)). Cell counts were derived from flow cytometry (gating strategy in Fig. S2), each dot represents an individual.


227 Comparison was performed across timepoints within each PFS groups, bold dashed line in the violins indicate median, light  
228 dotted lines lower and upper quartile. Student's t-test, \*  $p < 0.05$ , \*\*  $p < 0.01$ .

229

230 An increase in neutrophil count with inadequate T-cell and no NK-cell expansion after RTend was  
231 observed in the poor prognostic group (Fig. 2, Fig. S4). The intermediate and favorable prognostic  
232 groups showed peripheral NK-cell increase after RTend (Fig. S4) while the poor prognostic group did  
233 not (median value for intermediate group at RTend 0.014, at C.1 0.040, at C.2 0.132, at C.3 0.257  
234 Gcells/L; RTend-C.1  $p = 0.094$ , RTend-C.2  $p = 0.011$ , RTend-C.3  $p = 0.015$ ; median value for favorable  
235 group see Tab. S2). The favorable prognostic group showed increase after RTend of CD8+ T-cells  
236 (median value for intermediate group at RTend 0.14, at C.1 0.51, at C.2 0.42, at C.3 0.73 Gcells/L;  
237 RTend-C.1  $p = 0.0596$ , RTend-C.2  $p = 0.053$ , RTend-C.3  $p = 0.031$ ; median value for favorable group Tab.  
238 S2).

239 All patients experienced leukocytopenia following RT or cCRT (Fig. 1). We hypothesized that the  
240 change of lymphocytes within the first 6 mo after end of therapy might be most meaningful for  
241 therapy response as the immune system reconstitutes and can react to neoantigens released from  
242 destroyed tumor cells. To picture the dynamic processes during this phase between RTend-C.3 (6  
243 mo), AUC of the absolute cell counts of the major leukocyte subpopulations was calculated and  
244 compared to patient outcome.

245 Higher AUC for the period between RTend-C.3 reflect a more pronounced increase of absolute cell  
246 counts after therapy. Patients in the poor PFS group ( $PFS < 6$  mo) compared to the favorable  
247 prognostic group ( $PFS \geq 12$  mo) had significantly lower AUC for CD3+ T-cells ( $p = 0.0053$ ), CD4+ T-cells  
248 ( $p = 0.0026$ ), and NK-cells ( $p = 0.0008$ ) (Fig. 3). AUC of CD8+ T-cells, B-cells, eosinophils, and NLR were  
249 not different between the poor and good prognostic groups.



250


251 **Fig. 3** Standardized AUC (Z-score) for the interval RTend-C.3 of leukocyte subpopulations stratified according PFS groups  
 252 (PFS<6 mo (red), PFS ≥6<12 mo (grey), PFS ≥12 mo (green)). Cell counts were derived from flow cytometry (gating strategy  
 253 in Fig. S2), neutrophil, and eosinophil counts were determined by clinical chemistry routine lab (cICh). Each dot represents  
 254 the value of an individual, bold dashed line in the violins indicate median, light dotted lines lower and upper quartile.  
 255 Student's T test, \* p<0.05, \*\* p<0.01, \*\*\*<0.001.

256

### 257 **Unsupervised clustering reveals longer PFS for patients receiving ICI**

258 Normalized lymphocyte parameters were clustered by unsupervised hierarchical clustering. PFS,  
 259 treatment regimen, local relapse, distant metastases were annotated to, but were not included in  
 260 the clustering. The result (Fig. 4) identified two clusters: on the right side were patients with low AUC  
 261 for all cell types, except NLR (assigned "cold" group) (9 of 19 patients). Only 1 patient (1 of 9 patients)  
 262 within this group had received ICI. Most patients (7 of 9 patients) in this "cold" lymphocyte-reduced

263 group had developed local tumor recurrence (LR) after definitive therapy and only 2 (of 9) belonged  
 264 to the favorable group (PFS $\geq$ 12 mo). Patients clustering to the left (10 of 19 patients) had higher AUC  
 265 (RTend-C.3) for all leukocyte subpopulations except NLR (assigned “hot” group). Six of the patients of  
 266 the “hot” group had been treated with ICI (6 of 10), only 2 (of 10) had experienced LR and most  
 267 belonged to the favorable PFS group (7 of 19).



268  
 269 **Fig. 4** Heatmap of unsupervised clustering of AUC (RTend-C.3) of leukocyte subpopulations, every column represents a  
 270 patient, PFS (<6mo,  $\geq$ 6 <12mo, and  $\geq$ 12mo), treatment regime and recurrence (LR, local recurrence; DM, distant  
 271 metastases) (AUCs) in patients (n=19). Bold vertical line separates a “hot” group (higher AUC) and a left “cold” group (lower  
 272 AUC).  
 273

274

275 Fisher's Exact Testing "cold" or "hot" group against good or poor PFS ( $\geq 12$  mo 10 patients; and  $< 12$   
276 mo, 9 patients, respectively) revealed a statistically non-significant value of  $p=0.069$ . The Odds ratio  
277 (95% CI) was 7.17 (0.752, 113.47).


278

279 **Linear discriminant analysis (LDA) using blood cell subpopulations separates patients according to**

280 **PFS**

281 We analyzed the AUC of cell counts (CD4+ and CD8+ T-cells, B-cells, CD56+CD3- NK-cells, eosinophils,  
282 neutrophils, and the NLR) at the RTend to C.3 interval as predictor variables for PFS (response  
283 variable), defined in 3 groups: PFS $< 6$  mo,  $\geq 6 < 12$  mo, and  $\geq 12$  mo.

284 Discriminant markers for PFS $\geq 12$  mo (green area) were the AUCs of CD4+ T-cells, and CD56+ NK-cells  
285 (Fig. 5, Fig. S5). By these markers, 6 of 9 patients of the PFS $\geq 12$  mo group were correctly separated  
286 from the other PFS groups. Patients with intermediate PFS ( $\geq 6 < 12$  mo) (grey area) were  
287 discriminated by AUCs of B-cells and NLR, with four of five individuals of this group separated  
288 correctly. The mean of prediction as a measure for accuracy was 0.947 for linear discriminant  
289 analysis.




290

291 **Fig. 5** Linear discriminant analysis group plot (response variable PFS, predictor variables were AUCs of the interval RTend-  
292 C.3 of CD4+ T-cells, CD8+ T-cells, B-cells, NK-cells, eosinophils, neutrophils, and NLR). Mean as a measure for accuracy was  
293 0.947. The length and direction of the arrows indicate how well the parameter differentiates this group from the others.

294

### 295 **Variation in IL-6 concentration is correlated with PFS**

296 IL-6 is a pro-inflammatory cytokine that plays an important role in innate immunity and is  
297 upregulated in sepsis [6], after trauma [7], and medical treatment, e.g. surgery [8]. Basal IL-6 levels  
298 highly vary inter-individually [9], thus a comparison of absolute values for IL-6 across individuals is  
299 difficult to interpret. We focused on the intra-individual variation of IL-6 concentrations (pg/ml) over  
300 at least 3 consecutive timepoints, starting at RTend until C.3 as a clinically sensible interval for  
301 survival prediction. The standard deviation of the IL-6 concentrations (pg/ml) during this interval (n=4  
302 blood samples each patient) was used as a measure of variation of the IL-6 level.



303

304 Fig. 6 Standard deviation (SD) of IL-6 concentration from RTend-C.3 according to PFS groups (box plots showing median,  
305 min and max); Student's T test, \* p<0.05, \*\* p<0.01.

306

307 The favorable survival group had a median standard deviation (RTend-C.3) of 2.5 (range 0.7-6.6), the  
308 poor survival group 22.9 (range 2.3-175.7), and the intermediate group 8.8 (range 4.0-12.3). Thus,  
309 the IL-6 variation after RTend was significantly lower for the favorable PFS group and this significantly  
310 correlated with PFS (p=0.007, Fig. 6).

311

## 312 Discussion

313 In this prospective explorative study, we evaluated the dynamics of defined peripheral leukocyte  
314 subsets in patients with inoperable stage III NSCLC during primary treatment and follow-up with the  
315 aim to identify peripheral T-cell subsets that may predict treatment outcome, especially PFS.

316 Our analysis provides evidence that ALC expansion after the end of definitive RT or cCRT until 6 mo  
317 afterwards is significantly associated with treatment efficacy. Increase of AC in CD3+ T-cells, CD8+  
318 cytotoxic T-cells, and NK-cells had the most pronounced effect and was associated with favorable

319 PFS, whereas significant increase in B-cell counts had a less apparent positive association with PFS  
320 and eosinophils and CD4+ T-cell counts had no association.

321 ALC before treatment (A.1) or at any other single timepoint did not reveal a correlation with PFS (Fig.  
322 1). There was no significant correlation between ALC at six months after RTend and treatment  
323 regimen (data not shown).

324 Comparable to findings of previously published studies [10], [11], [12], [13], all patients in this study  
325 experienced moderate to severe lymphocytopenia during RT (A.2-RTend) with the nadir at the end of  
326 radiotherapy. Most of our patients recovered from lymphocytopenia within the following 3 (C.2) to 6  
327 (C.3) mo. Some (4 of 16 at C.3) had persistently low cell counts (Fig. 1), which correlated with poor  
328 disease control with PFS less than 6 mo (Fig. 3). An earlier study [14] found an association between  
329 severe lymphocytopenia (<500 cells/ $\mu$ l) and reduced OS (HR 1.70, p=0.17). Similar evidence was  
330 observed in glioblastoma [15], cervical cancer [16] and in seminoma [17]. This is comparable to what  
331 we see in this study, where patients with continuously low ALC had poor PFS and OS (Fig. S3c,d).

332 In our study patients had favorable PFS and OS when treated with cCRT+ICI compared to cCRT alone  
333 (Fig. S3e,f). In a comparable investigation, Jing et al. [18] compared NSCLC patients who received  
334 cCRT with those who received additionally maintenance treatment with durvalumab. They found a  
335 significant increase in PFS in the durvalumab subgroup alongside with a significant correlation  
336 between lymphocytopenia and PFS/OS. Jing et al. observed no statistically significant evidence that  
337 patients with lymphocytopenia benefited from durvalumab in terms of improved overall survival.

338 However, the authors focused on severe lymphocytopenia with a cell count of less than 0.23 Gcells/L  
339 (230 cells/ $\mu$ l). Additional factors may play a role when ALC is extremely low. Our cohort was small  
340 and only five patients had very low ALC at the end of radiation. Of these patients, two received RT,  
341 one cCRT, and two received cCRT+ICI. Two cCRT+ICI patients showed a strong recovery of cell counts  
342 together with favorable PFS ( $\geq$ 23 mo). Interestingly, Cho et al. [12] postulated that patients with



343 severe lymphocytopenia may benefit most from additional ICI because a fresh and immunological  
344 potent lymphocyte population may arise from a depleted lymphocyte reservoir.

345 The timeperiod following end of RT is considered to be significant since processes involving  
346 immunogenicity take place that play a role in durable immune activation and tumor rejection [19],  
347 [20]. In this study, we focused on the 6-mo period of RTend-C.3 and refer to it as a crucial recovery  
348 phase. Considering the different lymphocyte subtypes (Fig. 2), we identified that an early increase in  
349 absolute counts after RT of total CD3+ T-cells and CD8+ T-cells was predictive of favorable PFS.

350 Interestingly, Belka et al. [17] found that CD8+ T-cells recovered significantly faster than CD4+ T-cells  
351 after end of radiation treatment in patients with seminoma. In head and neck cancer, a gradual  
352 increase in CD8+ T-cells over 6 mo after radiotherapy was observed for non-recurrent patients [21].  
353 This supports our finding that an early increase in CD8+ T-cells in peripheral blood may be useful to  
354 predict favorable PFS. Kim et al. [22] reported on increasing frequency of Ki67+ cells within CD8+ PD-  
355 1+ T-cells in patients with locally advanced NSCLC during cCRT peaking at the last week during  
356 therapy followed by a decline 1-mo post-cCRT. These cells acquired a senescence phenotype.

357 Although we did not include the Ki67 marker in this study we did not see a decline of CD8+ T-cells but  
358 rather more CD8+ T-cells in absolute counts from C.1.

359

360 We assumed that the dynamic changes of the cell counts may be meaningful for patient survival.  
361 Evidence that T-cell recovery is important was shown in a study of melanoma patients by Huang et al.  
362 [20]. They found that a CD8+ Ki67+ T-cell subpopulation positively correlated with clinical outcome  
363 when it peaked at a given early timepoint after therapy begin and subsequently decreased. To reflect  
364 the dynamic changes in absolute cell count in given subpopulations during the recovery interval of  
365 Rtend-C.3, we calculate the AUC between four consecutive timepoints within 6 mo after RT (RTend-  
366 C.1-C.2-C.3). This new approach can depict a broader picture of cellular dynamics in peripheral blood  
367 than the stepwise comparison of single timepoints. We identified that total lymphocytes and  
368 neutrophils, CD3+ T-cells, B-cells and NK-cells recover significantly faster and reach significantly

369 higher AUC in patients with favorable PFS $\geq$ 12 mo. Considering the T-cell subsets in this study, the  
370 prediction of long-term survival using this AUC method was statistically significant with the CD4+ but  
371 not with CD8+ T-cells. We additionally used LDA as a classical approach in pattern recognition to  
372 define the cell subsets that contribute most to favorable outcome during the recovery phase [23]. A  
373 high value in AUC of CD4+ T-cells and NK-cells after RT end was found to correlate with a PFS $\geq$ 12 mo.  
374 High AUC of CD4+ T-cells and NK-cells as well as addition of ICI contributed mostly to favorable PFS,  
375 and a trend of fewer local recurrences in these patients was detected.

376 We also analyzed IL-6 plasma concentrations during and after treatment. In in-vitro experiments  
377 using human NSCLC cancer cell lines as well as mouse models, Yamaji et al. [24] found an association  
378 between IL-6 and tumor proliferation. The pro-inflammatory cytokine IL-6 has predictive potential of  
379 severity in a variety of diseases, e.g. heart disease [25], pneumonia [26]. Absolute IL-6 values are  
380 challenging to compare across individuals because of interindividual differences as well as  
381 dependency on gender, sex, and age [27]. Therefore, we interrogated the intra-individual dynamics  
382 of IL-6 within a 6-mo period following RT/cCRT using the standard deviation as a measure for the  
383 magnitude of this variation. We found a strong negative correlation of IL-6 variation with PFS, which  
384 is consistent with the findings of Yamaji et al. [24].

385

386 The current study has limitations. The study encompassed only a small number of patients (n=20)  
387 distributed over different treatment regimes. LDA may be problematic when used with small sample  
388 numbers [28]. To mitigate this issue, we interrogated a potential association with clinical benefit (OS,  
389 PFS) by various means including comparisons of single markers at individual timepoints or time  
390 intervals, as well as multi-parametric comparisons using unsupervised clustering and discriminatory  
391 analysis. Despite its limitations, our study has its value as it was conducted prospectively, and  
392 samples were collected longitudinally at multiple timepoints to characterize the recovery phase after  
393 RT. The results can be considered as a hypothesis to be tested in follow-up studies. If confirmed, the

394 two identified parameters, peripheral CD8+ T-cell counts and IL-6 plasma concentration after  
395 treatment, are immediately amenable to clinical practice. A follow-up study is in progress including  
396 40 inoperable stage III NSCLC patients [29].

397

### 398 **Conclusions**

399 The present findings suggest that two parameters, which are commonly assessed in clinical routine,  
400 can be used to predict patient outcome. An early increase in CD8+ T cell lymphocyte count and low  
401 standard deviation in IL-6 plasma concentration are significantly correlated to patients with  
402 favorable, respectively poor outcome (PFS) after definitive therapy independent of treatment  
403 scheme. If confirmed, the two identified parameters are immediately amenable to clinical practice.

404

405

406

### 407 **Declarations**

408 Ethics approval and consent to participate

409 The study was approved by the Human Ethics Committee of the Ludwig-Maximilians-University of  
410 Munich reference no. 17-632 and conducted in accordance with the Declaration of Helsinki. Patients  
411 were included into the study after informed consent.

412

### 413 **Acknowledgements**

414 We thank patients and their families, the clinicians and staff member of the LMU hospital, and  
415 colleagues at the Asklepios Fachkliniken München-Gauting.

416 For excellent support, we thank Anna Herbstritt, Barbara Mosetter, and Adam Slusarski.

417

418

419 **References**

- 420 1. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG,  
421 Groome P, Mitchell A, Bolejack V, et al: **The IASLC Lung Cancer Staging Project: Proposals for**  
422 **Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM**  
423 **Classification for Lung Cancer.** *J Thorac Oncol* 2016, **11**:39-51.
- 424 2. Ribas A, Wolchok JD: **Cancer immunotherapy using checkpoint blockade.** *Science* 2018,  
425 **359**:1350-1355.
- 426 3. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD: **Immune modulation in cancer**  
427 **with antibodies.** *Annu Rev Med* 2014, **65**:185-202.
- 428 4. Li S, Zhang C, Pang G, Wang P: **Emerging Blood-Based Biomarkers for Predicting Response to**  
429 **Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.** *Front Immunol* 2020,  
430 **11**:603157.
- 431 5. Hammer O: **PAST: Paleontological statistics software package for education and data**  
432 **analysis.** *Palaeontologia Electronica* 2001, **4**.
- 433 6. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer  
434 AJ, Thijs LG, Aarden LA: **Increased plasma levels of interleukin-6 in sepsis.** *Blood* 1989,  
435 **74**:1704-1710.
- 436 7. Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O'Keefe  
437 G, Sperry J, et al: **Early elevation in random plasma IL-6 after severe injury is associated**  
438 **with development of organ failure.** *Shock* 2010, **34**:346-351.
- 439 8. Cheng E, Shi Q, Shields AF, Nixon AB, Shergill AP, Ma C, Guthrie KA, Couture F, Kuebler P,  
440 Kumar P, et al: **Association of Inflammatory Biomarkers With Survival Among Patients With**  
441 **Stage III Colon Cancer.** *JAMA Oncol* 2023.
- 442 9. Said EA, Al-Reesi I, Al-Shizawi N, Jaju S, Al-Balushi MS, Koh CY, Al-Jabri AA, Jeyaseelan L:  
443 **Defining IL-6 levels in healthy individuals: A meta-analysis.** *J Med Virol* 2021, **93**:3915-3924.

- 444 10. Zhang J, Huang SH, Li H, Li Y, Chen XL, Zhang WQ, Chen HG, Gu LJ: **Preoperative lymphocyte**  
445 **count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer.**  
446 *Med Oncol* 2013, **30**:352.
- 447 11. Chen NB, Xiong M, Zhou R, Zhou Y, Qiu B, Luo YF, Zhou S, Chu C, Li QW, Wang B, et al: **CT**  
448 **radiomics-based long-term survival prediction for locally advanced non-small cell lung**  
449 **cancer patients treated with concurrent chemoradiotherapy using features from tumor and**  
450 **tumor organismal environment.** *Radiat Oncol* 2022, **17**:184.
- 451 12. Cho Y, Kim Y, Chamseddine I, Lee WH, Kim HR, Lee JJ, Hong MH, Cho BC, Lee CG, Cho S, et al:  
452 **Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in**  
453 **stage III NSCLC patients undergoing maintenance immunotherapy.** *Radiother Oncol* 2022,  
454 **168**:1-7.
- 455 13. Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW:  
456 **Lymphopenia association with gross tumor volume and lung V5 and its effects on non-**  
457 **small cell lung cancer patient outcomes.** *Int J Radiat Oncol Biol Phys* 2014, **89**:1084-1091.
- 458 14. Campian JL, Ye X, Brock M, Grossman SA: **Treatment-related lymphopenia in patients with**  
459 **stage III non-small-cell lung cancer.** *Cancer Invest* 2013, **31**:183-188.
- 460 15. Mohan R, Liu AY, Brown PD, Mahajan A, Dinh J, Chung C, McAvoy S, McAleer MF, Lin SH, Li J,  
461 et al: **Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia**  
462 **in glioblastoma patients: phase II randomized study of protons vs photons.** *Neuro Oncol*  
463 2021, **23**:284-294.
- 464 16. van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG,  
465 Cohen AF, Melief CJ, et al: **Impact of (chemo)radiotherapy on immune cell composition and**  
466 **function in cervical cancer patients.** *Oncoimmunology* 2017, **6**:e1267095.
- 467 17. Belka C, Ottinger H, Kreuzfelder E, Weinmann M, Lindemann M, Lepple-Wienhues A, Budach  
468 W, Grosse-Wilde H, Bamberg M: **Impact of localized radiotherapy on blood immune cells**  
469 **counts and function in humans.** *Radiother Oncol* 1999, **50**:199-204.

- 470 18. Jing W, Xu T, Wu L, Lopez PB, Grassberger C, Ellsworth SG, Mohan R, Hobbs BP,  
471 Blumenschein GR, Tu J, et al: **Severe Radiation-Induced Lymphopenia Attenuates the**  
472 **Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC.** *JTO Clin Res Rep*  
473 2022, **3**:100391.
- 474 19. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC: **Ionizing radiation**  
475 **inhibition of distant untreated tumors (abscopal effect) is immune mediated.** *Int J Radiat*  
476 *Oncol Biol Phys* 2004, **58**:862-870.
- 477 20. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR,  
478 Wenz B, et al: **T-cell invigoration to tumour burden ratio associated with anti-PD-1**  
479 **response.** *Nature* 2017, **545**:60-65.
- 480 21. Niu M, Combs SE, Linge A, Krause M, Baumann M, Lohaus F, Ebert N, Tinhofer I, Budach V,  
481 von der Grun J, et al: **Comparison of the composition of lymphocyte subpopulations in non-**  
482 **relapse and relapse patients with squamous cell carcinoma of the head and neck before,**  
483 **during radiochemotherapy and in the follow-up period: a multicenter prospective study of**  
484 **the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).** *Radiat Oncol* 2021,  
485 **16**:141.
- 486 22. Kim KH, Pyo H, Lee H, Oh D, Noh JM, Ahn YC, Yoon HI, Moon H, Lee J, Park S, et al: **Dynamics**  
487 **of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell**  
488 **Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy.** *Int J Radiat Oncol*  
489 *Biol Phys* 2022, **113**:415-425.
- 490 23. Ye J, Ji S: *Discriminant analysis for dimensionality reduction: An overview of recent*  
491 *developments; in Biometrics: Theory, Methods, and Applications.* Wiley IEEE Press, New York;  
492 2009.
- 493 24. Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, Motohashi S, Yokoi S, Hiroshima K,  
494 Tagawa M, et al: **Correlation between interleukin 6 production and tumor proliferation in**  
495 **non-small cell lung cancer.** *Cancer Immunol Immunother* 2004, **53**:786-792.

- 496 25. Zhang WR, Garg AX, Coca SG, Devereaux PJ, Eikelboom J, Kavsak P, McArthur E, Thiessen-  
497 Philbrook H, Shortt C, Shlipak M, et al: **Plasma IL-6 and IL-10 Concentrations Predict AKI and**  
498 **Long-Term Mortality in Adults after Cardiac Surgery.** *J Am Soc Nephrol* 2015, **26**:3123-3132.
- 499 26. Woiciechowsky C, Schonig B, Cobanov J, Lanksch WR, Volk HD, Docke WD: **Early IL-6 plasma**  
500 **concentrations correlate with severity of brain injury and pneumonia in brain-injured**  
501 **patients.** *J Trauma* 2002, **52**:339-345.
- 502 27. Wei J, Xu H, Davies JL, Hemmings GP: **Increase of plasma IL-6 concentration with age in**  
503 **healthy subjects.** *Life Sci* 1992, **51**:1953-1956.
- 504 28. Tharwat A, Gaber T, Ibrahim A, Hassanien AE: **Linear discriminant analysis: A detailed**  
505 **tutorial.** *Ai Communications* 2017, **30**:169-190.
- 506 29. Kasmann L, Taugner J, Eze C, Nieto A, Pelikan C, Florsch B, Kenndoff S, Hofer TP, Nossner E,  
507 Schulz C, et al: **Prospective evaluation of immunological, molecular-genetic, image-based**  
508 **and microbial analyses to characterize tumor response and control in patients with**  
509 **unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by**  
510 **consolidation therapy with durvalumab (PRECISION): protocol for a prospective**  
511 **longitudinal biomarker study.** *Transl Lung Cancer Res* 2022, **11**:1503-1509.
- 512